Cipla has inked a licensing agreement with Bio-Thera Solutions for its BAT1706 bevacizumab biosimilar, under which the Indian firm will have exclusive rights to distribute and sell the biosimilar of Genentech’s Avastin in “select emerging markets”.
Bio-Thera said that the partnership “will leverage Cipla’s strong local presence, sales and marketing capabilities in the select emerging
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?